Veterinary pharmacy pushes for specialty recognition

Veterinary pharmacy is edging toward formal recognition as a specialty, with the Board of Pharmacy Specialties now reviewing a petition to create a board-certified veterinary pharmacy credential. The move, highlighted in a recent Clinician’s Brief Veterinary Breakroom episode, reflects years of organizing by pharmacy groups that say animal medication management has become too complex to sit comfortably inside general pharmacy training alone. The fact that the topic is now being discussed in a clinician-facing format also suggests the proposal is resonating beyond pharmacy leadership circles and into day-to-day veterinary practice. (vetmeds.org)

The current push has been building for at least two years. In July 2024, BPS announced a veterinary pharmacy job analysis panel to determine whether the field had enough distinct practice functions, knowledge requirements, and workforce demand to justify specialty certification. By January 2025, ACVP board minutes said that job analysis was complete and recommendations had been sent to the BPS board for review, with leaders already discussing how to fund a petition phase if BPS gave the green light. (prnewswire.com)

That process advanced in January 2026, when ACVP, ICVP, and SVHP jointly submitted a petition asking BPS to recognize veterinary pharmacy as a specialty certification area. ACVP announced on February 26, 2026, that BPS had opened a public comment period, with comments due by April 1, 2026, and said the board would render a decision within six months. Pharmacy Times, citing the petition and BPS materials, reported that approval would trigger creation of a specialty council to set eligibility criteria and develop a certification exam item bank. (vetmeds.org)

Supporters’ case centers on the idea that veterinary pharmacy is not simply human pharmacy applied to smaller patients. ACVP says the work requires comparative pharmacology, toxicology, and One Health knowledge. The petition, as described by Pharmacy Times, argues that veterinary pharmacists must manage major interspecies differences in pharmacokinetics and pharmacodynamics, sparse FDA-approved veterinary drug options, excipient risks, compounding needs, and regulatory distinctions tied to whether an animal is a companion animal, a food-producing species, or part of research or public health work. It also points to practice settings that range from community and compounding pharmacies to veterinary teaching hospitals, zoos, aquariums, federal agencies, and animal health industry roles. (vetmeds.org)

Recent Veterinary Breakroom discussions help illustrate why supporters say that knowledge base is getting harder to treat as niche. One episode on monoclonal antibodies described how products such as lokivetmab helped open a new era of targeted biologics in veterinary medicine, with additional agents now used in pain management and other areas and market forecasts projecting rapid growth. Another episode explored “wait-and-see” prescriptions as an antimicrobial-stewardship strategy adapted from human medicine, raising practical questions about when delayed prescribing is appropriate and how it affects antibiotic use. Those conversations were not about pharmacy certification directly, but they reinforce the petitioners’ broader point: veterinary therapeutics are evolving quickly, and medication decisions increasingly involve specialized evidence, counseling, and stewardship considerations. Clinician’s Brief also recently highlighted broader systems issues such as uneven geographic access to veterinarians worldwide and the financial pressure of veterinary education debt, both of which shape how care is delivered and where outside medication expertise may become more valuable. Those episodes do not serve as direct evidence for specialty recognition, but they provide useful context for why advanced pharmacy support may be more relevant now than in the past.

There’s also an access argument behind the push. The International College of Veterinary Pharmacy says it already offers a Diplomate credential and oversees veterinary pharmacy residency accreditation, but that pathway remains relatively small. Pharmacy Times reported that petitioner Gigi Davidson said only about 75 pharmacists are currently credentialed through ICVP and that the existing pathway is not open to everyone practicing in the space. In that telling, BPS recognition could standardize the field and broaden the pipeline of pharmacists with advanced veterinary training. (svhp.org)

Expert and industry commentary has focused less on prestige and more on evidence. Davidson told dvm360, as quoted by Pharmacy Times, that BPS needs detailed examples showing how specialty recognition would improve patient care, public health, and workplace demand, not just general statements of support. Separately, a March 2026 dvm360 opinion piece argued that pharmacists often view veterinary prescriptions as a niche area because pharmacy education still leaves meaningful training gaps in animal therapeutics. That doesn’t prove a specialty is the only answer, but it does reinforce the petitioners’ claim that veterinary medication use requires knowledge many pharmacists do not routinely acquire in school. (pharmacytimes.com)

Why it matters: For veterinary professionals, specialty recognition could eventually make pharmacist collaboration more structured and more clinically useful, especially in areas like compounding oversight, antimicrobial stewardship, toxicology, pain management, food animal residue compliance, and medication counseling for pet parents. It may also help practices identify pharmacists with validated advanced training at a time when prescribing pathways are getting more complicated, more prescriptions are being filled outside the clinic, and newer drug classes such as monoclonal antibodies are expanding treatment options. The public-health framing also matters: as Clinician’s Brief noted in a separate discussion on global travel time to veterinary care, veterinary access affects not just animal welfare but food security and zoonotic disease response. Specialty-trained pharmacists would not solve those access gaps, but stronger medication expertise could still support safer, more scalable care models. At the same time, recognition alone won’t solve workforce shortages or access gaps, and some of the practical benefit will depend on whether certification standards remain broad enough to include pharmacists working outside academic veterinary hospitals. This last point is an inference based on current concerns about limited credentialing pathways and the stated goal of expanding access. (pharmacytimes.com)

What to watch: The immediate next step is BPS’s decision, expected within six months of the public comment opening in late February 2026. If the petition is approved, the field would move from advocacy into implementation: building a specialty council, defining eligibility, and creating an exam. If it is not approved, supporters will likely need to strengthen the workforce and public-health case with more data from practice, education, and regulatory stakeholders. Either way, the surrounding conversation in veterinary media suggests this is no longer just an internal pharmacy issue; it is becoming part of a wider discussion about how the profession manages increasingly complex therapeutics, stewardship demands, and access challenges. (vetmeds.org)